116 related articles for article (PubMed ID: 10445044)
1. New thrombin inhibitors based on D-cha-Pro-derivatives.
Steinmetzer T; Batdorsdhjin M; Kleinwächter P; Seyfarth L; Greiner G; Reissmann S; Stürzebecher J
J Enzyme Inhib; 1999; 14(3):203-16. PubMed ID: 10445044
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of potential thrombin inhibitors. Incorporation of tartaric acid templates as P2 proline mimetics.
Dahlgren A; Brånalt J; Kvarnström I; Nilsson I; Musil D; Samuelsson B
Bioorg Med Chem; 2002 May; 10(5):1567-80. PubMed ID: 11886818
[TBL] [Abstract][Full Text] [Related]
3. Preparation of L-proline based aeruginosin 298-A analogs: optimization of the P1-moiety.
Wang G; Goyal N; Hopkinson B
Bioorg Med Chem Lett; 2009 Jul; 19(14):3798-803. PubMed ID: 19447619
[TBL] [Abstract][Full Text] [Related]
4. Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor.
Rupin A; Mennecier P; Lila C; de Nanteuil G; Verbeuren TJ
Thromb Haemost; 1997 Oct; 78(4):1221-7. PubMed ID: 9364988
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the two-step pathway for inhibition of thrombin by alpha-ketoamide transition state analogs.
Lewis SD; Lucas BJ; Brady SF; Sisko JT; Cutrona KJ; Sanderson PE; Freidinger RM; Mao SS; Gardell SJ; Shafer JA
J Biol Chem; 1998 Feb; 273(9):4843-54. PubMed ID: 9478925
[TBL] [Abstract][Full Text] [Related]
6. [Synthesis of N-alpha-(arylsulfonyl)-4-amidino-phenylalanyl-prolines and N-alpha-(arylsulfonylglycyl)-4-amidino-phenylalanyl-prolines and testing of them as inhibitors of serine proteinases. 33. Synthetic inhibitors of serine proteinases].
Voigt B; Stürzebecher J; Wagner G; Markwardt F
Pharmazie; 1988 Jun; 43(6):412-4. PubMed ID: 2974999
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of thrombin by arginine-containing peptide chloromethyl ketones and bis chloromethyl ketone-albumin conjugates.
Odake S; Kam CM; Powers JC
J Enzyme Inhib; 1995; 9(1):17-27. PubMed ID: 8568563
[TBL] [Abstract][Full Text] [Related]
8. Incorporation of neutral C-terminal residues in 3-amidinophenylalanine-derived matriptase inhibitors.
Schweinitz A; Dönnecke D; Ludwig A; Steinmetzer P; Schulze A; Kotthaus J; Wein S; Clement B; Steinmetzer T
Bioorg Med Chem Lett; 2009 Apr; 19(7):1960-5. PubMed ID: 19250826
[TBL] [Abstract][Full Text] [Related]
9. Design of selective thrombin inhibitors based on the (R)-Phe-Pro-Arg sequence.
Danilewicz JC; Abel SM; Brown AD; Fish PV; Hawkeswood E; Holland SJ; James K; McElroy AB; Overington J; Powling MJ; Rance DJ
J Med Chem; 2002 Jun; 45(12):2432-53. PubMed ID: 12036353
[TBL] [Abstract][Full Text] [Related]
10. Beyond heparinization: design of highly potent thrombin inhibitors suitable for surface coupling.
Steinmetzer T; Baum B; Biela A; Klebe G; Nowak G; Bucha E
ChemMedChem; 2012 Nov; 7(11):1965-73. PubMed ID: 22907907
[TBL] [Abstract][Full Text] [Related]
11. Benzyloxycarbonyl-D-Phe-Pro-methoxypropylboroglycine: a novel inhibitor of thrombin with high selectivity containing a neutral side chain at the P1 position.
Claeson G; Philipp M; Agner E; Scully MF; Metternich R; Kakkar VV; DeSoyza T; Niu LH
Biochem J; 1993 Mar; 290 ( Pt 2)(Pt 2):309-12. PubMed ID: 8452516
[TBL] [Abstract][Full Text] [Related]
12. New inhibitors of thrombin and other trypsin-like proteases: hydrogen bonding of an aromatic cyano group with a backbone amide of the P1 binding site replaces binding of a basic side chain.
Lee SL; Alexander RS; Smallwood A; Trievel R; Mersinger L; Weber PC; Kettner C
Biochemistry; 1997 Oct; 36(43):13180-6. PubMed ID: 9341205
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Evaluation of Spumigin Analogues Library with Thrombin Inhibitory Activity.
Žula A; Będziak I; Kikelj D; Ilaš J
Mar Drugs; 2018 Oct; 16(11):. PubMed ID: 30373260
[TBL] [Abstract][Full Text] [Related]
14. Structure/function aspects of neutral P1 residue peptide inhibitors of thrombin.
Deadman J; Claeson G; Scully MF
J Enzyme Inhib; 1995; 9(1):29-41. PubMed ID: 8568564
[TBL] [Abstract][Full Text] [Related]
15. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
[TBL] [Abstract][Full Text] [Related]
16. Highly selective tripeptide thrombin inhibitors.
Shuman RT; Rothenberger RB; Campbell CS; Smith GF; Gifford-Moore DS; Gesellchen PD
J Med Chem; 1993 Feb; 36(3):314-9. PubMed ID: 8426361
[TBL] [Abstract][Full Text] [Related]
17. Molecular design and characterization of an alpha-thrombin inhibitor containing a novel P1 moiety.
Malikayil JA; Burkhart JP; Schreuder HA; Broersma RJ; Tardif C; Kutcher LW; Mehdi S; Schatzman GL; Neises B; Peet NP
Biochemistry; 1997 Feb; 36(5):1034-40. PubMed ID: 9033393
[TBL] [Abstract][Full Text] [Related]
18. Mechanism-based isocoumarin inhibitors for blood coagulation serine proteases. Effect of the 7-substituent in 7-amino-4-chloro-3-(isothioureidoalkoxy)isocoumarins on inhibitory and anticoagulant potency.
Kam CM; Kerrigan JE; Plaskon RR; Duffy EJ; Lollar P; Suddath FL; Powers JC
J Med Chem; 1994 Apr; 37(9):1298-306. PubMed ID: 8176707
[TBL] [Abstract][Full Text] [Related]
19. Protease inhibitors, part 13: Specific, weakly basic thrombin inhibitors incorporating sulfonyl dicyandiamide moieties in their structure.
Clare BW; Scozzafava A; Supuran CT
J Enzyme Inhib; 2001 Jan; 16(1):1-13. PubMed ID: 11496831
[TBL] [Abstract][Full Text] [Related]
20. Novel non-covalent azaphenylalanine thrombin inhibitors with an aminomethyl or amino group at the P1 position.
Obreza A; Stegnar M; Urleb U
Pharmazie; 2004 Sep; 59(9):659-67. PubMed ID: 15497744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
